Plasma metabolomics for the assessment of the progression of non-small cell lung cancer. Issue 1 (March 2023)

• Record Type: Journal Article
• Authors: Zhang, Yingtian; Cheng, Yaping; Qin, Liqiang; Liu, Yuanliang; Huang, Sijia; Dai, Liya; Tao, Jialong; Pan, Jie; Su, Cunjin; Zhang, Yusong
• Is Part Of: International journal of biological markers. Volume 38:Issue 1(2023)
• Page Start: 37
• Page End: 45
• Publication Date: 2023-03
• Subjects: Non-small cell lung cancer -- metabolomics -- biomarkers -- UPLC-MS/MS; Cell receptors -- Periodicals; Histochemistry -- Periodicals; Tumor markers -- Periodicals; Tumor antigens -- Periodicals; 616.99407582
• DOI: 10.1177/03936155221137359
• Languages: English
• ISSNs: 0393-6155

Abstract

Objectives: Non-small cell lung cancer (NSCLC) is a leading type of lung cancer with a high mortality rate worldwide. Although many procedures for the diagnosis and prognosis assessment of lung cancer exist, they are often laborious, expensive, and invasive. This study aimed to develop an ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC–MS/MS)-based analysis method for the plasma biomarkers of NSCLC with the potential to indicate the stages and progression of this malignancy conveniently and reliably. Methods: A total of 53 patients with NSCLC in early stages (I–III) and advanced stage (IV) were classified into the early and advanced groups based on the tumor node metastasis staging system. A comprehensive metabolomic analysis of plasma from patients with NSCLC was performed via UPLC–MS/MS. Principal component analysis and partial least squares–discriminant analysis were conducted for statistical analysis. Potential biomarkers were evaluated and screened through receiver operating characteristic analyses and correlation analysis. Main differential metabolic pathways were also identified by utilizing metaboanalyst. Results: A total of 129 differential metabolites were detected in accordance with the criteria of VIP ≥ 1 and a P -value of ≤ 0.05. The receiver operating characteristic curves indicated that 11 of these metabolites have the potential to be promising markers of disease progression. Apparent correlated metabolites were also filtered out. Furthermore, the 11 most predominant metabolic pathways with alterations involved in NSCLC were identified. Conclusion: Our study focused on the plasma metabolomic changes in patients with NSCLC. These changes may be used for the prediction of the stage and progression of NSCLC. Moreover, we discussed the metabolic pathways wherein the altered metabolites were mainly enriched.